Latest revision as of 21:53, 20 December 2023

@@ Line 1: / Line 1: @@
-'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].'''
+<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
-Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
+<big>'''This is an obsolete page; please follow the links below to find the page you're looking for.'''</big>
-{{TOC limit|limit=3}}
-=Autologous (auto) stem cell transplant=
+=[[Stem cell mobilization]]=
-==BEAC==
-BEAC: '''<u>B</u>'''iCNU, '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C, '''<u>C</u>'''yclophosphamide
-===Regimen ===
+=[[Autologous_HSCT|Autologous stem cell transplant]]=
-<span
+=[[Allogeneic_HSCT|Allogeneic hematopoietic cell transplant, myeloablative]]=
-style="background:#00CD00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase III</span>
-''Autologous blood stem cells are infused on day 0.''
+=[[Allogeneic_HSCT|Allogeneic hematopoietic cell transplant, reduced-intensity conditioning (RIC)]]=
-*[[Carmustine (BiCNU)]] 300 mg/m2 IV once on day -7
-*[[Etoposide (Vepesid)]] 800 mg/m2 IV once per day on days -6 to -3
-*[[Cytarabine (Cytosar)]] 800 mg/m2 IV once per day on days -6 to -3
-*[[Cyclophosphamide (Cytoxan)]] 35 mg/kg IV once per day on days -6 to -3
-Supportive medications:
+[[Category:Obsolete pages]]
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting on day +1, continued until there are 3 consecutive days with ANC ≥1000
-*Prophylaxis against opportunistic infections and management of febrile neutropenia per "active protocols"
-===References===
-# Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008 Jan;87(1):43-8. Epub 2007 Aug 21. [http://www.springerlink.com/content/r764139714772803/ link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17710401 PubMed]
-==BEAM==
-BEAM: '''<u>B</u>'''iCNU, '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C, '''<u>M</u>'''elphalan
-===Regimen #1, Jo et al. 2008===
-<span
-style="background:#00CD00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase III</span>
-''Autologous blood stem cells are infused on day 0.''
-*[[Carmustine (BiCNU)]] 300 mg/m2 IV once on day -6
-*[[Etoposide (Vepesid)]] 200 mg/m2 IV once per day on days -5 to -2
-*[[Cytarabine (Cytosar)]] 400 mg/m2 IV once per day on days -5 to -2
-*[[Melphalan (Alkeran)]] 140 mg/m2 IV once on day -1
-Supportive medications:
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting on day +1, continued until there are 3 consecutive days with ANC ≥1000
-*Prophylaxis against opportunistic infections and management of febrile neutropenia per "active protocols"
-===Regimen #2, Shimoni et al. 2012===
-<span
-style="background:#00CD00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Randomized Phase II, >20 per arm</span>
-''Autologous blood stem cells are infused on day 0.''
-*[[Carmustine (BiCNU)]] 300 mg/m2 IV once on day -6
-*[[Etoposide (Vepesid)]] 200 mg/m2 IV once per day on days -5 to -2
-*[[Cytarabine (Cytosar)]] 200 mg/m2 IV Q12H on days -5 to -2
-*[[Melphalan (Alkeran)]] 140 mg/m2 IV once on day -1
-Supportive medications:
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting on day +4 "until engraftment"
-*[[Valacyclovir (Valtrex)]] (dose not specified) for one month
-*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] (dose/frequency not specified) for six months
-===Regimen #3, Stewart et al. 2006===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-''Autologous blood stem cells are infused on day 0.''
-*[[Carmustine (BiCNU)]] 300 mg/m2 IV once on day -6
-*[[Etoposide (Vepesid)]] 100 mg/m2 IV Q12H on days -5 to -2 (8 total doses)
-*[[Cytarabine (Cytosar)]] 200 mg/m2 IV Q12H on days -5 to -2 (8 total doses)
-*[[Melphalan (Alkeran)]] 140 mg/m2 IV once on day -1
-Supportive medications:
-*Patients <70 kg: [[Filgrastim (Neupogen)]] 300 mcg SC once per day starting on day +7 after stem cell transplant
-*Patients >70 kg (reference did not clarify which dosage to use for patients who are exactly 70 kg): [[Filgrastim (Neupogen)]] 480 mcg SC once per day starting on day +7 after stem cell transplant
-*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] (160/800 mg) PO BID on Monday and Thursdays, until 6 months after BEAM
-''While ANC <500:''
-*[[Ciprofloxacin (Cipro)]] 500 mg PO BID
-*[[Fluconazole (Diflucan)]] 100 mg PO once per day or mycostatin 500,000 units swish & swallow QID
-*[[Acyclovir (Zovirax)]] 400 mg PO TID
-===Regimen #4, Josting et al. 2005===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-''Paper did not specify which day peripheral blood stem cells were administered.''
-*[[Carmustine (BiCNU)]] 300 mg/m2 IV once on day 1
-*[[Etoposide (Vepesid)]] 150 mg/m2 IV Q12H on days 2 to 5 (8 total doses)
-*[[Cytarabine (Cytosar)]] 200 mg/m2 IV Q12H on days 2 to 5 (8 total doses)
-*[[Melphalan (Alkeran)]] 140 mg/m2 IV once on day 1
-===Regimen #5, Gisselbrecht et al. 2010===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Non-randomized</span>
-''This study randomized patients to R-ICE or R-DHAP, but all patients undergoing autologous transplant received BEAM''
-''Autologous blood stem cells are infused on day 0, at least 24 hours after completion of BEAM.''
-*[[Carmustine (BiCNU)]] 300 mg/m2 IV once on day -6
-*[[Etoposide (Vepesid)]] 200 mg/m2 IV once per day on days -5 to -2
-*[[Cytarabine (Cytosar)]] 200 mg/m2 IV once per day on days -5 to -2
-*[[Melphalan (Alkeran)]] 140 mg/m2 IV once on day -1
-===Regimen #6, Zinzani et al. 2003===
-<span
-style="background:#ff0000;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Retrospective</span>
-*[[Carmustine (BiCNU)]] 300 mg/m2 IV once on day -7
-*[[Etoposide (Vepesid)]] 200 mg/m2 IV BID on days -6 to -3
-*[[Cytarabine (Cytosar)]] 200 mg/m2 IV BID on days -6 to -3
-*[[Melphalan (Alkeran)]] 140 mg/m2 IV once on day -2
-===References===
-# '''Retrospective:''' Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, de Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Giudice V, Zompatori M, Stefoni V, Alinari L, Musuraca G, Bassi S, Conte R, Pileri S, Tura S, Baccarani M. High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience. Haematologica. 2003 May;88(5):522-8. [http://www.haematologica.org/content/88/5/522.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12745271 PubMed]
-# Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, De Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Guidice V, Zompatori M, Stefoni V, Alinari L, Musuraca G, Marchi E, Bassi S, Conte R, Pileri S, Tura S, Baccarani M. High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma. 2004 Feb;45(2):321-6. [http://www.ncbi.nlm.nih.gov/pubmed/15101718 PubMed]
-# Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dörken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol. 2005 Aug;16(8):1359-65. Epub 2005 Jun 6. [http://annonc.oxfordjournals.org/content/16/8/1359.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15939712 PubMed]
-# Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L, Morris DG, Jones A, Brown C, Russell JA. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2006 Jun 15;107(12):4623-7. Epub 2006 Feb 7. [http://bloodjournal.hematologylibrary.org/content/107/12/4623.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16467197 PubMed] content property of [http://hemonc.org HemOnc.org]
-# Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008 Jan;87(1):43-8. Epub 2007 Aug 21. [http://www.springerlink.com/content/r764139714772803/ link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17710401 PubMed]
-# Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 Sep 20;28(27):4184-90. Epub 2010 Jul 26. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896. [http://jco.ascopubs.org/content/28/27/4184.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20660832 PubMed]
-# Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012 Oct 1;118(19):4706-14. Epub 2012 Jan 17. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.27418/full link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/22252613 PubMed]
-==Bor-HDM==
-Bor-HDM: '''<u>Bor</u>'''tezomib, '''<u>H</u>'''igh '''<u>D</u>'''ose '''<u>M</u>'''elphalan
-===Regimen===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-''Autologous hematopoetic stem cell transplant on day 0.''
-*[[Bortezomib (Velcade)]] 1 mg/m2 IV once per day on days -6, -3, 1, 4
-*[[Melphalan (Alkeran)]] 200 mg/m2 IV once on day -2
-Supportive medications:
-*"All patients received standard supportive care measures"
-===References===
-# Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D, Hulin C, Fruchart C, Marit G, Pégourié B, Lenain P, Araujo C, Kolb B, Randriamalala E, Royer B, Stoppa AM, Dib M, Dorvaux V, Garderet L, Mathiot C, Avet-Loiseau H, Harousseau JL, Attal M; Intergroupe Francophone du Myélome (IFM). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood. 2010 Jan 7;115(1):32-7. Epub 2009 Nov 2. [http://bloodjournal.hematologylibrary.org/content/115/1/32.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19884643 PubMed]
-==Busulfan & Melphalan==
-===Regimen===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-''Day 0 is the day of transplantation.''
-*[[Busulfan (Myleran)]] 1 mg/kg PO q6h on days -6 to -4
-*[[Melphalan (Alkeran)]] 70 mg/m2 IV bolus once per day on days -3 & -2
-===References===
-# Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N; Japan Adult Leukemia Study Group. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 Apr 18;121(16):3095-102. Epub 2013 Feb 14. [http://bloodjournal.hematologylibrary.org/content/121/16/3095.long link to original article] '''Contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23412094 PubMed]
-==C-VAMP -> high-dose Melphalan (Alkeran)==
-C-VAMP: '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin, '''<u>M</u>'''ethyl'''<u>P</u>'''rednisolone
-===Regimen - multiple myeloma high-dose therapy===
-<span
-style="background:#00CD00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase III</span>
-====Induction therapy====
-*[[Cyclophosphamide (Cytoxan)]] 500 mg IV once per day on days 1, 8, 15
-**Cyclophosphamide was omitted in patients with a serum creatinine >3.4 mg/dL
-*[[Vincristine (Oncovin)]] 0.4 mg IV once per day on days 1 to 4 (total dose per cycle: 1.6 mg)
-*[[Doxorubicin (Adriamycin)]] 9 mg/m2/day IV continuous infusion over 4 days (total dose per cycle: 36 mg/m2) on days 1 to 4
-*[[Methylprednisolone (Solumedrol)]] 1000 mg/m2 (maximum dose per cycle of 1500 mg) PO/IV once per day on days 1 to 5
-'''21-day cycles, given until maximal response was achieved. A minimum of 3 cycles given before stem cell harvest.'''
-*Stem cell mobilization was performed with administration of [[Cyclophosphamide (Cytoxan)]] 2000 to 4000 mg/m2 IV with hydration and [[Filgrastim (Neupogen)|G-CSF]] on days 5 to 12
-====Melphalan (Alkeran) & transplant====
-*[[Melphalan (Alkeran)]] 200 mg/m2 IV (no additional details given)
-*Peripheral blood stem cells infused on day 0, 24 hours after melphalan
-*[[Methylprednisolone (Solumedrol)]] 1500 mg IV once per day on days 0 to 3
-An alternative to the above melphalan option was:
-*Bone marrow autograft
-*Total body irradiation (TBI)
-*[[Melphalan (Alkeran)]] 140 mg/m2 IV (no additional details given)
-*[[Methylprednisolone (Solumedrol)]] 1500 mg IV once per day on days 0 to 3
-====Interferon alfa maintenance therapy====
-*[[Interferon alfa-2a (Roferon-A)]] 3 million units SC three times per week
-===References===
-# Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003 May 8;348(19):1875-83. [http://www.nejm.org/doi/full/10.1056/NEJMoa022340#t=abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12736280 PubMed]
-==CBV==
-CBV: '''<u>C</u>'''yclophosphamide, '''<u>B</u>'''iCNU, '''<u>V</u>'''P-16
-===Regimen #1, Stiff et al. 1998; Damon et al. 2009===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-*[[Carmustine (BiCNU)]] 15 mg/kg (maximum dose of 550 mg/m2) IV over 1 hour once on day -6
-*[[Etoposide (Vepesid)]] 60 mg/kg IV over 4 hours once on day -4
-*[[Cyclophosphamide (Cytoxan)]] 100 mg/kg IV over 2 hours once on day -2
-*Autologous blood stem cells infused on day 0.
-Supportive medications:
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting on day +4, to continue until ANC >5000 once or >1500 twice
-*[[Levofloxacin (Levaquin)]] 500 mg PO once per day, starting on day +2, to continue until ANC ≥500
-*[[Fluconazole (Diflucan)]] 200 mg PO once per day, starting on day +1, to continue until ANC ≥500
-*[[Acyclovir (Zovirax)]] 200 mg PO TID, starting on day -2, to continue until 1 year after ASCT
-*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO BID on Saturday and Sunday, to continue until 3 months after ASCT
-===Regimen #2, Zinzani et al. 2003 (CVB)===
-*[[Cyclophosphamide (Cytoxan)]] 1500 mg/m2 IV once per day on days -6 to -3
-*[[Etoposide (Vepesid)]] 250 mg/m2 IV once per day on days -6 to -4
-*[[Carmustine (BiCNU)]] 300 mg/m2 IV once on day -6
-===References===
-# Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. J Clin Oncol. 1998 Jan;16(1):48-55. [http://jco.ascopubs.org/content/16/1/48.full.pdf+html link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/9440722 PubMed]
-# '''Retrospective:''' Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, de Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Giudice V, Zompatori M, Stefoni V, Alinari L, Musuraca G, Bassi S, Conte R, Pileri S, Tura S, Baccarani M. High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience. Haematologica. 2003 May;88(5):522-8. [http://www.haematologica.org/content/88/5/522.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12745271 PubMed]
-# Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20;27(36):6101-8. Epub 2009 Nov 16. [http://jco.ascopubs.org/content/27/36/6101.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19917845 PubMed]
-==Cyclophosphamide (Cytoxan), Etoposide (Vepesid), TBI==
-===Regimen===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-''Autologous hematopoetic stem cell transplant on day 0.''
-*[[Cyclophosphamide (Cytoxan)]] 100 mg/kg IV over 1 to 2 hours once on day -2
-*[[Etoposide (Vepesid)]] 60 mg/kg IV over 4 hours once on day -4
-*Total body irradiation (TBI) with 150 cGy fractions given twice per day (fractions are at least 5 hours apart) x 8 fractions (total dose: 1200 cGy) over 4 days on days -8 to -5, with lung shielding for the final 600 Gy
-**Note: Table 1 of Stiff et al. 1998 lists the dosage of each fraction as being 120 cGy, in contrast to the body text under "treatment regimen" saying each fraction is 150 cGy.  It is believed that the 150 cGy dose is correct since 8 fractions of this results in the correct total dose of 1200 cGy.
-Supportive medications:
-*[[Diphenhydramine (Benadryl)]] 25 mg (route not specified) once 2 hours before [[Etoposide (Vepesid)]] to prevent allergic reaction
-*[[Hydrocortisone (Cortef)]] 100 mg (route not specified) once 2 hours before [[Etoposide (Vepesid)]] to prevent allergic reaction
-*"Continuous bladder irrigation and vigorous hydration were used" to protect against hemorrhagic cystitis
-===References===
-# Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. J Clin Oncol. 1998 Jan;16(1):48-55. [http://jco.ascopubs.org/content/16/1/48.full.pdf+html link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/9440722 PubMed]
-==DHAP --> BEAC & Transplant==
-DHAP: '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (cytarabine), cis'''<u>P</u>'''latin
-BEAC: '''<u>B</u>'''iCNU, '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C, '''<u>C</u>'''yclophosphamide
-===Regimen===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-====Induction Therapy====
-*[[Dexamethasone (Decadron)]] 40 mg PO/IV once per day on days 1 to 4
-*[[Cytarabine (Cytosar)]] 2 g/m2 IV over 3 hours on day 3, followed by another infusion 12 hours later
-*[[Cisplatin (Platinol)]] IV continuous infusion over 24 hours on day 1
-Supportive Medications:
-*Normal saline solution with mannitol, 50 g/L, at 250 ml/hour IV over 36 hours
-*[[Metoclopramide (Reglan)]] 1 mg/kg "given routinely as antiemetics"
-*[[Diphenhydramine (Benadryl)]] 25 mg IV "given routinely as antiemetics"
-'''21 to 28 day cycles, depending on degree of myelosuppression, for total of 2 cycles'''
-''After 1 course of DHAP, patients underwent bone marrow harvest. A second course of DHAP was administered, after which patients were restaged. Patients who showed a response then underwent involved field radiotherapy if bulky disease was present at initial relapse''
-====BEAC & transplant====
-''Autologous blood stem cells are infused on day 0.''
-*[[Carmustine (BiCNU)]] 300 mg/m2 IV once on day -6
-*[[Etoposide (Vepesid)]] 100 mg/m2 IV twice per day on days -5 to -2
-*[[Cytarabine (Cytosar)]] 100 mg/m2 IV twice per day on days -5 to -2
-*[[Cyclophosphamide (Cytoxan)]] 35 mg/kg IV once per day on days -5 to -2
-*[[Mesna (Mesnex)]] 50 mg/kg IV every day on days -5 to -2 (optional)
-===References===
-# Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, Spitzer G, Velasquez W, Weisenburger DD, Fernandez-Ranada J, et al. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood. 1991 Apr 1;77(7):1587-92. [http://www.bloodjournal.org/content/77/7/1587.long?sso-checked=1 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/2009374 PubMed}
-==High-dose Melphalan (Alkeran)==
-===Regimen - immunoglobulin light-chain (AL) amyloidosis===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-''Eligibility criteria: Biopsy-proven amyloid disease and ≥1 major organ involved, evidence of plasma cell dyscrasia, no heart failure or arrhythmia that cannot be medically managed, cardiac ejection fraction ≥40%, no pleural effusions, supine systolic blood pressure ≥90 mmHg, O2 saturation ≥95% on room air, lung diffusing capacity ≥50% predicted, SWOG performance status ≤2 unless due to neuropathy.''
-*Patients who fulfilled all of these criteria--≤65 years old, cardiac ejection fraction ≥45%, and ≥2.5 x 10<sup>6</sup> CD34+ cells/kg collected--received [[Melphalan (Alkeran)]] 200 mg/m2 total dose IV divided over two consecutive days
-*Patients with at least one of these criteria-->65 years old, cardiac ejection fraction 40-44%, or with 2.0-2.5 x 10<sup>6</sup> CD34+ cells/kg collected received [[Melphalan (Alkeran)]] 140 mg/m2 total dose IV divided over two consecutive days
-*Autologous stem cell infusion occurs 24 to 72 hours after the last dose of melphalan
-===References===
-# Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004 Jan 20;140(2):85-93. [http://annals.org/article.aspx?articleid=717091 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/14734330 PubMed]
-==TAM6==
-===Regimen===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-*Total body irradiation (TBI) with a total dose of 10 Gy over 3 days using twice per day fractions
-*[[Cytarabine (Cytosar)]] 1500 mg/m2 IV Q12H x 2 days (total of 4 total doses)
-*[[Melphalan (Alkeran)]] 140 mg/m2 IV
-'''Peripheral stem cells are infused on day 0'''
-Supportive medications:
-"Antimicrobial prophylaxis and use of [[Filgrastim (Neupogen) | G-CSF]] or erythropoietin were permitted according to physician decision."
-===References===
-# Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, Salles G, Van Hoof A, Casasnovas O, Brousse N, Lefrere F, Hermine O; for the Groupe d'Etude des Lymphomes de l'Adulte (GELA). CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood. 2013 Jan 3;121(1):48-53. Epub 2012 Jun 20. [http://bloodjournal.hematologylibrary.org/content/121/1/48.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22718839 PubMed]
-==VMCP & BVAP -> high-dose Melphalan (Alkeran)==
-VMCP: '''<u>V</u>'''incristine, '''<u>M</u>'''elphalan, '''<u>C</u>'''yclophosphamide, '''<u>P</u>'''rednisone
-<br>BVAP: '''<u>B</u>'''iCNU, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin, '''<u>P</u>'''rednisone
-===Regimen - multiple myeloma high-dose therapy===
-<span
-style="background:#00CD00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase III</span>
-====VMCP induction therapy====
-*[[Vincristine (Oncovin)]] 1 mg IV once on day 1
-*[[Melphalan (Alkeran)]] 5 mg/m2 PO once per day on days 1 to 4
-*[[Cyclophosphamide (Cytoxan)]] 110 mg/m2 PO once per day on days 1 to 4
-*[[Prednisone (Sterapred)]] 60 mg/m2 PO once per day on days 1 to 4
-'''21-day cycles x 2 to 3 cycles, given in an alternating fashion with BVAP'''
-====BVAP induction therapy====
-*[[Vincristine (Oncovin)]] 1 mg IV once on day 1
-*[[Carmustine (BiCNU)]] 30 mg/m2 IV once on day 1
-*[[Doxorubicin (Adriamycin)]] 30 mg/m2 IV once on day 1
-*[[Prednisone (Sterapred)]] 60 mg/m2 PO once per day on days 1 to 4
-'''21-day cycles x 2 to 3 cycles, given in an alternating fashion with VMCP'''
-'''VMCP and BVAP are given in an alternating fashion x a total of 4 to 6 cycles'''; patients with a [[performance status|WHO performance status]] <3, creatinine <1.7 mg/dL (150 μmol/L), and bone marrow (collected after cycle 4) with greater than 200 million nucleated cells/kg would proceed to melphalan, total body irradiation (TBI), and transplant:
-====Melphalan (Alkeran), TBI, and transplant====
-*[[Melphalan (Alkeran)]] 140 mg/m2 IV (no other details given about its administration)
-*Total body irradiation (TBI) with a total dose of 8 Gy given over 4 days in 4 fractions, without lung shielding
-*Autologous hematopoietic stem cell transplant after melphalan and TBI
-*[[Interferon alfa-2b (Intron-A)‎|Interferon alfa]] treatment started after transplant when ANC >1500/mm3 and platelets >75,000/mm3
-===References===
-# Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996 Jul 11;335(2):91-7. [http://www.nejm.org/doi/full/10.1056/NEJM199607113350204 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8649495 PubMed]
-==Z-BEAM==
-Z-BEAM: '''<u>Z</u>'''evalin, '''<u>B</u>'''iCNU, '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C, '''<u>M</u>'''elphalan
-===Regimen, Shimoni et al. 2012===
-<span
-style="background:#00CD00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Randomized Phase II, >20 per arm</span>
-''Autologous blood stem cells are infused on day 0.''
-*[[Rituximab (Rituxan)]] 250 mg/m2 IV once on day -14
-*[[Ibritumomab tiuxetan (Zevalin)|Ibritumomab tiuxetan & Yttrium-90 (Zevalin) ]] 0.5 mCi/kg (maximum dose of 32 mCi) IV once on day -14, given after [[Rituximab (Rituxan)]]
-*[[Carmustine (BiCNU)]] 300 mg/m2 IV once on day -6
-*[[Etoposide (Vepesid)]] 200 mg/m2 IV once per day on days -5 to -2
-*[[Cytarabine (Cytosar)]] 200 mg/m2 IV Q12H on days -5 to -2
-*[[Melphalan (Alkeran)]] 140 mg/m2 IV once on day -1
-Supportive medications:
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting on day +4 "until engraftment"
-*[[Valacyclovir (Valtrex)]] (dose not specified) for one month
-*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] (dose/frequency not specified) for six months
-===References===
-# Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012 Oct 1;118(19):4706-14. Epub 2012 Jan 17. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.27418/full link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/22252613 PubMed]
-# Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernsández M, González-Barca E, López D, Caballero D. Autologous stem cell transplantation after conditioning with Yttrium-90 ibritumomab tiuxetan plus beam in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2013 Oct 25. [Epub ahead of print] [http://www.haematologica.org/content/99/3/505.full link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24162789 PubMed]
-=Allogeneic (allo) stem cell transplant=
-==BEAM==
-BEAM: '''<u>B</u>'''iCNU, '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C, '''<u>M</u>'''elphalan
-===Regimen===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-''Day 0 is the day of transplantation.''
-*[[Carmustine (BiCNU)]] 300 mg/m2 IV once on day -6
-*[[Etoposide (Vepesid)]] 200 mg/m2 IV BID on days -5 to -2
-*[[Cytarabine (Cytosar)]] 200 mg/m2 IV BID on days -5 to -2
-*[[Melphalan (Alkeran)]] 140 mg/m2 IV once on day -1
-Supportive medications:
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day +7 and continued until engraftment
-*GVHD prophylaxis with [[Tacrolimus (Prograf)]] and [[Methotrexate (MTX)]]
-*"Prophylactic antibiotics"
-===References===
-# Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Körbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May;10(5):527-32. [http://annonc.oxfordjournals.org/content/10/5/527.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10416001 PubMed]
-==Busulfan & Cyclophosphamide (BuCy)==
-===Regimen #1, Lee et al. 2013===
-<span
-style="background:#00CD00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase III</span>
-''Day 0 is the day of transplantation.''
-*[[Busulfan (Myleran)]] 3.2 mg/kg IV once per day on days -7 to -4
-*[[Cyclophosphamide (Cytoxan)]] 60 mg/kg IV once on days -3 and -2
-Supportive medications:
-*"[[Cyclosporine non-modified (Sandimmune)|Cyclosporine]] alone or cyclosporine plus [[Methotrexate (MTX)|methotrexate]] according to the discretion of the attending physician"
-*[[Filgrastim (Neupogen)]] 450 mcg SC once per day, starting on day +5 and continued until ANC >3,000
-===Regimen #2, Copelan et al. 2013===
-<span
-style="background:#ff0000;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Retrospective</span>
-''This was a retrospective study from CIBMTR data; regimen and supportive medication details vary.''
-*[[Busulfan (Myleran)]]
-*[[Cyclophosphamide (Cytoxan)]]
-===References===
-# Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, Lee JH, Lee WS, Park JH, Bae SH, Hyun MS, Kim DY, Kim SD, Min YJ, Lee KH. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013 Feb 20;31(6):701-9. Epub 2012 Nov 5. [http://jco.ascopubs.org/content/31/6/701.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23129746 PubMed]
-# Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 5;122(24):3863-70. Epub 2013 Sep 24. [http://bloodjournal.hematologylibrary.org/content/122/24/3863.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24065243 PubMed]
-==Busulfan & Fludarabine (Flu/Bu; BuFlu)==
-===Regimen #1, Russell et al. 2002 (Flu/Bu)===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-''Day 0 is the day of transplantation.''
-*[[Fludarabine (Fludara)]] 50 mg/m2 IV once per day on days -6 to -2
-*[[Busulfan (Myleran)]] 3.2 mg/kg (ideal body weight) IV once per day over 3 hours on days -5 to -2
-Supportive medications:
-*[[Phenytoin (Dilantin)]] "loading" PO/IV, dosed to maintain therapeutic levels of 40 to 80 umol/L on days -5 to -2
-*[[Ciprofloxacin (Cipro)]] 500 mg PO BID as prophylaxis
-*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] (dose not specified in reference, but assume 160/800 mg dose) PO 2 times a week as PCP prophylaxis
-*No routine fungal prophylaxis
-*No routine use of growth factors
-*CMV negative blood
-Acute GVHD prophylaxis:
-*[[Antithymocyte globulin (ATG)|Antithymocyte globulin (Thymoglobulin, rabbit ATG)]] 0.5 mg/kg IV once on day -2; 2 mg/kg/day IV once on days -1 and 0 (total dose of 4.5 mg/kg)
-*[[Cyclosporine modified (Neoral)]] or [[Cyclosporine non-modified (Sandimmune)]] PO/IV BID, with doses adjusted to maintain cyclosporine levels of 150 to 400 umol/L
-*[[Methotrexate (MTX)]] 15 mg/m2 once on day 1; 10 mg/m2 once per day on days 3, 6, 11
-*[[Folinic acid (Leucovorin)]] 5 mg started 24 hours after each dose of [[Methotrexate (MTX)]] and continued Q6H until 12 hours before the next dose of [[Methotrexate (MTX)]]
-===Regimen #2, Lee et al. 2013 (BuFlu)===
-<span
-style="background:#00CD00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase III</span>
-''Day 0 is the day of transplantation.''
-*[[Busulfan (Myleran)]] 3.2 mg/kg IV once per day on days -7 to -4
-*[[Fludarabine (Fludara)]] 30 mg/m2 IV once per day on days -6 to -2
-Supportive medications:
-*"[[Cyclosporine non-modified (Sandimmune)|Cyclosporine]] alone or with [[Methotrexate (MTX)|methotrexate]] according to the discretion of the attending physician"
-*[[Filgrastim (Neupogen)]] 450 mcg SC once per day, starting on day +5 and continued until ANC >3,000
-===References===
-# Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8(9):468-76. [http://www.bbmt.org/article/S1083-8791%2802%2950007-0/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12374451 PubMed]
-# Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, Lee JH, Lee WS, Park JH, Bae SH, Hyun MS, Kim DY, Kim SD, Min YJ, Lee KH. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013 Feb 20;31(6):701-9. Epub 2012 Nov 5. [http://jco.ascopubs.org/content/31/6/701.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23129746 PubMed]
-==Cyclophosphamide and TBI==
-===Regimen, Copelan et al. 2013===
-<span
-style="background:#ff0000;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Retrospective</span>
-''This was a retrospective study from CIBMTR data; regimen and supportive medication details vary.''
-*[[Cyclophosphamide (Cytoxan)]]
-*Total body irradiation (TBI)
-===References===
-# Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 5;122(24):3863-70. Epub 2013 Sep 24. [http://bloodjournal.hematologylibrary.org/content/122/24/3863.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24065243 PubMed]
-==Fludarabine and Low-dose TBI==
-===Regimen===
-<span
-style="background:#00CD00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase III</span>
-''Day 0 is the day of transplantation.''
-*[[Fludarabine (Fludara)]] 30 mg/m2 IV once per day on days -4 to -2
-*Total body irradiation (TBI) 2 Gy at a rate of 0.07 to 0.20 Gy/min on day 0
-Supportive medications for GVHD prophylaxis:
-*"Postgrafting immunosuppression consisted of [[Cyclosporine non-modified (Sandimmune) | cyclosporine]] or [[Tacrolimus (Prograf) | tacrolimus]] combined with [[Mycophenolate mofetil (CellCept) | mycophenolate mofetil]]," further details not specified
-===References===
-# Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT, Bruno B, Petersen FB, Maris MB, Agura E, Yeager A, Bethge W, Sahebi F, Appelbaum FR, Maloney DG, Sandmaier BM. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010 Jun 10;28(17):2859-67. Epub 2010 May 3. [http://jco.ascopubs.org/content/28/17/2859.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20439626 PubMed]
-==Fludarabine, Busulfan, Cyclophosphamide==
-===Regimen, Glass et al. 2014 (DSHNHL R3)===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Nonrandomized</span>
-''This is described by the authors as a lymphoma-directed myeloablative conditioning regimen''
-====Conditioning====
-*[[Fludarabine (Fludara)]] 25 mg/m2/day IV on days -8 to -4
-*[[Busulfan (Myleran)]] 4 mg/kg/day PO or 3.2 mg/kg/day IV on days -6 to -4
-*[[Cyclophosphamide (Cytoxan)]] 60 mg/kg/day IV on days -3 and -2
-'''Day 0 is the day of transplantation'''
-====GVHD prophylaxis====
-*[[Tacrolimus (Prograf)]] 8 to 12 μg/L (route/frequency not specified) starting on day -1, tapered from day +100 in absence of GVHD
-*[[Mycophenolate mofetil (CellCept)]] 1000 mg (route not specified) BID from day +1 to +28
-*[[Antithymocyte globulin (ATG)|Antithymocyte globulin (Thymoglobulin, rabbit ATG)]] 2 mg/kg IV from day -3 to -1 (''unclear if this is a total dose or a daily dose; option also to use ATG-Fresenius S at a higher dose of 10 mg/kg)
-===References===
-<!-- # Glass B, rabbits Kamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M Silling G, Wilhelm C, Zeis M, Görlitz A, Pfeiffer S, Hilgers R, Truemper L, Schmitz N. High-dose chemotherapy Followed by allogeneic stem cell transplantation in relapsed and refractory high-risk aggressive non-Hodgkin's lymphoma: Results of a prospective study of the German high-grade non-Hodgkin's lymphoma study group. J Clin Oncol 30, 2012 (suppl; abstr 8004) -->
-# Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, Silling G, Wilhelm C, Zeis M, Görlitz A, Pfeiffer S, Hilgers R, Truemper L, Schmitz N; on behalf of the German High-Grade Lymphoma Study Group. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014 May 9. [Epub ahead of print] [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70161-5/fulltext link to original article] [http://www.dshnhl.org/app/download/9495510598/Studienprotokoll+DSHNHL+alloFBC+final+vollst.pdf link to original protocol (in German)] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/24827808 PubMed]
-==Fludarabine, Cyclophosphamide, & TBI for dUCB or haploidentical transplant==
-dUCB: '''<u>d</u>'''ouble '''<u>U</u>'''mbilical '''<u>C</u>'''ord '''<u>B</u>'''lood
-===Regimen #1, Brunstein et al. 2011 - dUCB transplantation===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-''Day 0 is the day of transplantation.''
-*[[Fludarabine (Fludara)]] 40 mg/m2 IV once per day on days -6 to -2 (total dose: 200 mg/m2)
-*[[Cyclophosphamide (Cytoxan)]] 50 mg/kg IV once on day -6
-*Total body irradiation (TBI) 2 Gy once on day -1
-Supportive medications:
-*[[Mesna (Mesnex)]] (dose/route/schedule not specified) and "vigorous IV hydration for uroprotection."
-*[[Filgrastim (Neupogen)]] 5 μg/kg SC once per day, starting on day +1, continued until ANC ≥2000/μL for 3 consecutive days
-====GVHD Prophylaxis====
-*[[Mycophenolate mofetil (CellCept)]] 1000 mg (route not specified) Q8H for patients >50 kg, starting on day -3 "and continuing until day +30 or 7 days after engraftment, whichever was later"
-**Patients <50 kg received [[Mycophenolate mofetil (CellCept)]] 15 mg/kg (route not specified) Q8H, starting on day -3 "and continuing until day +30 or 7 days after engraftment, whichever was later"
-*[[Cyclosporine modified (Neoral)|Cyclosporine A]] ([[Cyclosporine modified (Neoral)|Neoral]] vs. [[Cyclosporine non-modified (Sandimmune)|Sandimmune]] not specified, route not specified) with a goal trough of 200 to 400 ng/mL (starting date not specified) until day +100.  Patients without GVHD had their dose tapered by 10% each week starting on day +101, with discontinuation of cyclosporine A around day +180 to +200.
-*[[Tacrolimus (Prograf)]] (route not specified) with a goal trough level of 5 to 10 ng/mL could be substituted for cyclosporine.
-===Regimen #2, Brunstein et al. 2011 - Haploidentical===
-<span
-style="background:#EEEE00;
-padding:3px 6px 3px 6px;
-border-color:black;
-border-width:2px;
-border-style:solid;">Phase II</span>
-''Day 0 is the day of transplantation.''
-*[[Fludarabine (Fludara)]] 30 mg/m2 IV once per day on days -6 to -2 (total dose: 150 mg/m2)
-*[[Cyclophosphamide (Cytoxan)]] 14.5 mg/kg IV once on days -6 and -5
-*Total body irradiation (TBI) 2 Gy once on day -1
-Supportive medications:
-*[[Mesna (Mesnex)]] (dose/route/schedule not specified) and "vigorous IV hydration for uroprotection."
-*[[Filgrastim (Neupogen)]] 5 μg/kg SC once per day, starting on day +5, continued until ANC ≥1000/μL for 3 consecutive days
-====GVHD Prophylaxis====
-*[[Cyclophosphamide (Cytoxan)]] 50 mg/kg IBW IV over 1 to 2 hours once per day on days +3 (60 to 72 hours after marrow infusion) and +4
-*[[Mycophenolate mofetil (CellCept)]] 15 mg/kg (maximum daily dose of 3000 mg; route not specified) Q8H, starting on day +5, continued until day +35 or longer at physician discretion if active GVHD was present
-*[[Tacrolimus (Prograf)]] (route not specified) with a goal trough level of 5 to 10 ng/mL, starting on day +5, continued until day +180
-===References===
-# Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV;Blood and Marrow Transplant Clinical Trials Network. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011 Jul 14;118(2):282-8. [http://bloodjournal.hematologylibrary.org/content/118/2/282.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21527516 PubMed]